Perceptive Advisors Llc - Aug 23, 2021 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role
Director
Signature
/s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its investment manager, By: Joseph Edelman, its managing member
Stock symbol
CERE
Transactions as of
Aug 23, 2021
Transactions value $
$4,833,885
Form type
4
Date filed
8/25/2021, 07:14 PM
Previous filing
Aug 19, 2021
Next filing
Aug 31, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Purchase $1.15M +44.4K +0.92% $25.78 4.89M Aug 23, 2021 See Footnote F1, F4
transaction CERE Common Stock Purchase $1.93M +69.8K +1.43% $27.73 4.96M Aug 24, 2021 See Footnote F2, F4
transaction CERE Common Stock Purchase $1.75M +61.4K +1.24% $28.57 5.02M Aug 25, 2021 See Footnote F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.25 to $26.66, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.
F2 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.38 to $28.28, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.
F3 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.36 to $29.48, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.
F4 The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Mr. Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.